effect
initi
specif
antitumor
immun
vivo
vitro
investig
mani
research
focus
induct
adequ
tumor
antigenspecif
effector
cell
purpos
tumor
antigen
tumorassoci
antigen
prepar
vitro
express
produc
recombin
peptid
clone
construct
recombin
dna
vaccin
load
dendrit
cell
dc
make
dc
effort
devot
effici
conjug
tumor
antigen
cell
immun
toler
could
broken
mani
studi
reveal
promis
result
inhibit
tumor
growth
inhibit
elong
anim
surviv
anim
tumor
model
howev
tumor
multipl
genet
diseas
target
one
two
signal
molecul
tumor
cell
may
enough
inhibit
use
tumor
lysat
tumor
antigen
develop
util
mani
tumor
cell
line
modifi
way
prove
effect
strategi
inhibit
studi
show
undesir
result
induc
specif
antitumor
immun
other
manifest
potenti
antitumor
advantag
use
tumor
lysat
antigen
provid
feasibl
avenu
target
multipl
site
tumor
cell
variou
attempt
made
enhanc
antigen
tumor
lysat
pluse
dc
tumor
lysat
combin
cytokin
eg
gmcsf
tumor
lysat
method
demonstr
efficaci
tumor
type
despit
use
tumor
lysat
potenti
antitumor
vaccin
prove
valuabl
tool
transport
cpg
oligonucleotid
import
compon
earli
immun
respons
demonstr
vivo
cell
activ
occur
cpg
odn
deliveri
immun
system
antigenspecif
cell
activ
associ
presum
cellassoci
phase
requir
deliveri
signal
tlr
ligand
cpg
effici
evok
tumor
lysateinduc
antitumor
immun
tumor
lysat
antigen
immun
cell
respons
need
improv
recent
decad
agonist
toll
like
receptor
cpg
oligodeoxynucleotid
cpg
odn
display
potenti
adjuv
variou
vaccin
due
strong
immun
stimul
base
biolog
activ
cpg
odn
divid
b
c
class
aclass
cpg
odn
mainli
induc
plasmacytoid
dendrit
cell
pdc
secret
larg
amount
therebi
indirectli
activ
nk
cell
bclass
cpg
odn
strongli
stimul
strong
b
cell
nk
cell
activ
cytokin
cclass
cpg
odn
share
properti
aclass
bclass
cpg
test
whether
cpg
odn
could
enhanc
antitumor
effect
tumor
cell
lysatebas
tumor
vaccin
cclass
cpg
odn
use
adjuv
induc
antitumor
immun
respons
melanoma
mice
femal
mice
purchas
beij
vital
river
laboratori
anim
co
ltd
beij
laboratori
anim
research
center
maintain
isol
cage
specif
pathogenfre
condit
mice
use
week
age
experiment
manipul
mice
undertaken
accord
nation
institut
health
guid
care
use
laboratori
anim
approv
scientif
investig
board
scienc
technolog
jilin
provinc
human
pbmc
isol
buffi
coat
blood
center
jilin
provinc
china
ficollhypaqu
densiti
gradient
centrifug
pharmacia
wash
three
time
iscov
modifi
dulbecco
medium
gibco
viabil
pbmc
determin
trypan
blue
exclus
murin
melanoma
cell
origin
vero
cell
african
green
monkey
kidney
cell
line
american
type
cultur
collect
grown
iscov
modifi
dulbecco
medium
gibco
supplement
heatinactiv
fb
gibco
penicillin
streptomycin
mm
glutamin
humidifi
air
contain
cultur
cell
harvest
wash
three
time
phosphat
buffer
salin
pb
ph
cell
resuspend
pb
concentr
cell
lysat
prepar
five
cycl
freez
thaw
vigor
mix
use
vortex
mixer
total
lysi
cell
verifi
trypan
blue
dye
exclus
stain
lysat
supernat
precipit
separ
centrifug
min
precipit
dilut
volum
supernat
pb
cell
use
fifth
passag
nucleaseresist
phosphorothioatemodifi
odn
synthes
sangon
biotech
compani
shanghai
china
cpg
sequenc
dilut
te
buffer
tri
edta
ph
use
pyrogenfre
reagent
test
endotoxin
use
limulu
amebocyt
lysat
assay
associ
cape
cod
inc
cpg
odn
dilut
pb
use
vivo
day
tumor
challeng
tumor
cell
harvest
rins
three
time
pb
cell
resuspend
pb
administ
sc
ip
volum
ml
per
mous
prophylact
protocol
femal
mice
week
old
inject
sc
tumor
cell
lysat
cpg
odn
tumor
cell
lysat
plu
cpg
odn
pb
day
control
mice
given
pb
day
mice
challeng
tumor
cell
subcutan
inocul
right
hind
leg
sc
tumor
burden
model
tumor
cell
intraperiton
inocul
abdomen
ip
tumor
burden
model
therapeut
protocol
mice
inject
sc
tumor
cell
per
mous
sc
tumor
burden
model
day
immun
tumor
cell
lysat
cpg
odn
tumor
cell
lysat
plu
cpg
odn
day
neg
control
mice
given
pb
mice
weigh
everi
day
tumor
grown
certain
volum
mice
kill
spinal
disloc
tumor
remov
length
width
tumor
measur
vernier
calip
well
tumor
measur
use
tumor
size
calcul
follow
tumor
index
tumor
weight
mg
bodi
weight
g
surviv
mice
monitor
pbmc
incub
without
cpg
odn
h
cell
abdomin
lavag
fluid
wash
twice
fac
stain
buffer
pb
supplement
bsa
mm
edta
analyz
express
variou
cell
surfac
molecul
stain
fitclabel
mab
mab
use
dilut
respect
follow
analysi
mice
inject
pb
lysat
cpg
odn
lysat
plu
cpg
odn
day
day
third
immun
splenocyt
prepar
cultur
day
mitomycin
ctreat
cell
iscov
modifi
dulbecco
medium
gibco
supplement
vv
fb
uml
human
humidifi
air
contain
ratio
splenocyt
mitomycin
ctreat
cell
cultur
live
cell
isol
ficol
paqu
pharmacia
densiti
centrifug
assay
ctl
activ
cytotox
lymphocyt
ctl
activ
measur
fluorometr
briefli
target
cell
first
label
final
concentr
accord
manufactur
instruct
room
temperatur
label
stop
incub
equal
volum
heatinactiv
fb
room
temperatur
wash
pb
target
cell
label
carboxyfluorescein
diacet
succinimidyl
ester
cfse
briefli
cfse
dilut
final
concentr
ad
target
cell
suspens
immedi
follow
addit
cfse
equal
volum
fb
ad
stop
reaction
final
target
cell
wash
twice
pb
resuspend
medium
dispens
duplic
cellswel
ubottom
plate
effector
cell
incub
label
target
cell
variou
e
effector
cell
target
cell
ratio
h
centrifug
cell
pellet
resuspend
fac
stain
buffer
immedi
analyz
fac
calibur
posit
cell
gate
cell
number
acquir
sampl
percentag
specif
cell
lysi
target
cell
popul
determin
disappear
antigen
label
target
cfsehi
popul
compar
fluoresc
control
target
cfsehi
popul
calcul
specif
lysi
follow
equat
use
specif
lysi
mean
cfsehi
experi
groupmean
cfsehi
spontan
releas
vivo
vitro
experi
perform
least
three
time
use
oneway
analysi
varianc
anova
analyz
data
shown
nonparametr
analysi
use
analyz
data
shown
median
surviv
estim
kaplanmei
method
evalu
logrank
test
p
valu
consid
statist
signific
statist
analys
perform
spss
softwar
studi
use
cpg
agonist
adjuv
tumor
cell
lysat
determin
effect
tumor
growth
inhibit
mice
shown
fig
bablc
mice
sc
inject
lysat
plu
lysat
pb
inguin
groov
three
time
day
challeng
melanoma
cell
ip
day
fig
result
demonstr
lysat
plu
cpg
could
significantli
elong
mice
surviv
time
group
p
fig
observ
tumor
growth
abdomin
caviti
day
day
posttumor
inocul
two
mice
group
sacrif
observ
tumor
metastasi
abdomin
caviti
result
signifi
tumor
spread
throughout
abdomin
caviti
includ
greater
omentum
mesenteri
diaphragm
mice
inject
pb
mice
treat
tumor
lysat
cpg
fig
histopatholog
larg
number
melanoma
cell
detect
omentum
mice
administr
pb
contrast
mice
administr
lysat
plu
cpg
odn
show
significantli
less
chang
omentum
tissu
fig
demonstr
cpg
combin
lysat
could
initi
specif
antitumor
immun
mice
inject
lysat
lysat
plu
cpg
cpg
alon
pb
three
time
weekli
splenocyt
isol
day
third
immun
cultur
mitomycin
c
treat
tumor
cell
gener
effector
cell
result
effector
cell
cocultur
doublestain
cfse
target
cell
ratio
h
also
use
cell
neg
control
target
cell
data
shown
result
show
lysat
alon
display
specif
antitumor
effect
wherea
cpg
alon
fail
show
specif
antitumor
effect
expectedli
cpg
plu
lysat
display
stronger
specif
antitumor
respons
lysat
alon
p
fig
suggest
cpg
assist
lysat
induc
tumor
antigenspecif
cytotox
immun
respons
next
antilys
antibodi
sera
mice
detect
use
indirect
elisa
tumor
lysat
coat
antigen
subsequ
result
demonstr
serum
antibodi
level
mice
treat
lysat
mice
treat
lysat
plu
cpg
increas
day
immun
antibodi
level
significantli
increas
mice
treat
lysat
plu
cpg
group
immun
p
fig
confirm
whether
cpg
odn
plu
lysat
would
induc
immun
memori
melanoma
cell
mice
select
six
tumorfre
mice
undergon
cpg
odn
plu
lysat
immun
three
time
day
cell
inocul
model
live
day
observ
specif
antitumor
immun
respons
mice
use
neg
control
experiment
mice
rechalleng
cell
result
demonstr
mice
die
day
cell
wherea
mice
die
lysat
plu
cpg
group
fig
data
suggest
cpg
could
assist
lysat
gener
melanoma
specif
immunolog
memori
mice
delay
type
hypersent
dth
respons
gener
consid
primari
measur
mice
abl
immun
specif
tumor
antigen
light
studi
effect
cpg
plu
lysat
tumor
antigenspecif
dth
respons
mice
surviv
first
tumor
challeng
cpg
plu
lysat
treat
inject
tumor
lysat
left
hind
foot
pad
pb
right
hind
foot
serv
control
mice
inject
tumor
lysat
left
hind
foot
pb
right
hind
foot
result
show
mice
treat
cpg
plu
lysat
tumor
lysat
left
foot
exhibit
notic
swell
p
right
foot
pb
exhibit
notic
swell
fig
howev
mice
exhibit
swell
feet
result
demonstr
mice
treat
cpg
plu
lysat
antigen
specif
lysat
determin
specif
antitumor
immun
induc
cpg
plu
lysat
next
investig
proport
activ
lymphocyt
spleen
vaccin
mice
mice
immun
tumor
lysat
plu
cpg
sc
three
time
interv
immun
mice
challeng
ip
melanoma
cell
tumor
cell
challeng
spleen
isol
stain
differ
fluorescencelabel
antibodi
analyz
posit
cell
flow
cytometri
mice
inject
pb
serv
neg
control
posit
cell
decreas
spleen
isol
cpg
plu
lysat
immun
mice
challeng
tumor
cell
compar
spleen
pb
inject
mice
likewis
spleen
isol
cpg
plu
lysat
immun
mice
display
significantli
higher
posit
cell
compar
spleen
isol
mice
immun
pb
contrast
number
cell
spleen
chang
proport
nk
cell
posit
cell
mice
immun
cpg
plu
lysat
lower
pb
group
contrast
number
cell
spleen
chang
fig
next
investig
kinet
lymphocyt
around
local
site
tumor
burden
infiltr
lymphocyt
greater
omentum
periton
lavag
cell
periton
lavag
stain
differ
fluorescencelabel
antibodi
analyz
posit
cell
flow
cytometri
pbsinject
mice
use
neg
control
proport
cell
much
higher
mice
immun
control
group
number
decreas
eventu
becam
lower
pb
group
cell
cell
number
increas
decreas
cell
number
cell
lysat
cpg
group
higher
pb
group
cell
cell
number
increas
mice
immun
lysat
cpg
group
particularli
p
vs
pb
group
cell
increas
significantli
mice
immun
lysat
plu
significantli
decreas
fig
significantli
differ
pb
group
lysat
cpg
group
data
shown
result
show
nk
cell
may
play
import
role
earli
process
tumor
format
antitumor
effect
lysat
cpg
may
alter
determin
efficaci
cpg
plu
lysat
mice
inocul
cell
intraperiton
inject
tumor
model
use
valu
effect
cpg
assist
tumor
lysat
induc
antitumor
immun
mice
immun
procedur
prophylact
administr
therapeut
model
metastasi
model
tumor
volum
surviv
rate
mice
calcul
tumor
challeng
result
show
immun
lysat
cpg
extend
surviv
mice
p
vs
cpg
group
fig
subcutan
tumor
model
use
evalu
effect
cpg
assist
tumor
lysat
induc
antitumor
immun
mice
tumor
growth
mice
immun
lysat
cpg
significantli
inhibit
compar
mice
immun
either
pb
lysat
p
vs
pb
vs
lysat
tumor
grew
significantli
slower
lysat
cpg
compar
mice
immun
pb
lysat
differ
cpg
alon
fig
tumor
growth
mice
immun
day
antitumor
immun
rate
tumor
group
cpg
cumul
surviv
show
similar
trendenc
tumor
growth
addit
immun
lysat
cpg
could
significantli
elong
surviv
rate
mice
vs
pb
vs
lysat
wherea
immun
cpg
alon
effect
fig
use
therapeut
model
mice
inject
tumor
cell
sc
immun
tumor
cell
lysat
cpg
tumor
cell
lysat
cpg
day
result
demonstr
immun
lsyat
cpg
nt
protect
mice
tumor
growth
nt
extend
surviv
time
p
fig
result
reveal
cpg
effect
assist
tumor
lysat
induct
antitumor
effect
use
subcutan
tumor
model
mice
studi
shown
cpg
demonstr
characterist
cclass
cpg
odn
could
facilit
tumor
cell
lysat
induc
vigor
antitumor
activ
tumor
mice
prophylact
therapeut
found
combin
tumor
cell
lysat
cpg
inhibit
growth
melanoma
prolong
surviv
tumorbear
mice
addit
cpg
plu
tumor
cell
lysat
caus
gener
tumor
specif
immun
memori
induc
specif
cytotox
lymphocyt
helper
lymphocyt
mice
cell
may
higher
affin
cclass
cpg
odn
share
structur
characterist
biolog
function
bclass
cpg
odn
cpg
sequenc
differ
aclass
sequenc
primari
structur
howev
cpg
sequenc
similar
c
bclass
cpg
odn
previou
work
show
cclass
cpg
odn
could
induc
product
mix
ifn
includ
least
subtyp
import
nk
cell
mediat
antitumor
immun
support
evid
nk
cell
activ
aclass
cpg
odn
could
induc
tumor
reject
varieti
mous
tumor
especi
weakli
immunogen
tumor
melanoma
cpg
promot
human
pbmc
cell
enhanc
cpg
therebi
enhanc
hla
import
antigen
present
effici
th
cell
demonstr
directli
induc
cytostat
effect
tumor
cell
indirectli
activ
innat
immun
cell
includ
nk
cell
macrophag
kill
tumor
cell
good
antigen
deliveri
system
could
target
antigen
present
cell
prolong
antigen
present
prevent
degrad
regard
mechan
adjuv
action
cpg
possess
high
effici
induc
earli
strong
cytokin
chemokinerich
environ
site
inject
cpg
also
activ
nk
cell
experi
express
pbmc
result
suggest
cpg
valid
induc
natur
immun
respons
well
adapt
immun
respons
cpg
use
antitumor
research
notic
cpg
inhibit
tumor
growth
upon
subcutan
inject
tumor
drain
lymph
node
tdln
area
mice
compar
result
prophylact
model
found
use
cpg
alon
effect
may
attribut
abil
tumor
cell
provid
suffici
tumor
antigen
upon
cpg
odn
usag
base
result
vivo
subcutan
intraperiton
inject
cpg
tumor
cell
lysat
could
trigger
effect
antitumor
immun
respons
howev
combin
tumor
cell
lysat
cpg
lead
effect
immun
respons
suggest
cpg
tumor
cell
lysat
play
role
immun
respons
analysi
lymphocyt
transform
differ
tumor
inocul
locat
suggest
tcell
significantli
increas
within
h
tumor
inocul
howev
littl
chang
nk
cell
treg
cell
upon
tumor
inocul
indic
may
involv
immun
respons
result
ctl
assay
show
cell
immun
activ
use
cpg
alon
caus
effect
ctl
respons
cpg
combin
tumor
cell
lysat
gener
specif
ctl
howev
studi
cpg
adjuv
cancer
immunotherapi
limit
result
show
cpg
combin
tumor
cell
lysat
could
gener
strong
cell
respons
tumor
cell
consid
tumor
cell
lysat
alon
ca
nt
effect
caus
antitumor
immun
respons
mice
hypothes
besid
cell
lymphocyt
also
involv
antitumor
respons
dth
data
mous
surviv
show
degre
foot
pad
swell
mice
within
combin
group
much
higher
control
group
indic
cell
involv
immun
respons
ctl
dth
data
suggest
cell
cell
involv
immun
respons
caus
combin
tumor
cell
lysat
cpg
result
conclud
combin
tumor
cell
lysat
induc
differenti
cell
effect
assist
cell
result
howev
differ
result
exampl
combin
peptid
vaccin
caus
cell
respons
depend
assist
cell
addit
specif
ctl
caus
solubl
protein
vaccin
plu
cpg
odn
requir
helper
cell
believ
cpg
odn
induct
differ
immun
respons
may
associ
differ
type
tumor
antigen
furthermor
observ
cell
level
enhanc
pb
combin
group
presum
lymphocyt
increas
could
produc
effect
immun
respons
tumor
must
inhibit
effect
two
group
result
suggest
otherwis
therefor
hypothes
number
lymphocyt
increas
organ
receiv
extern
stimuli
whether
increas
lymphocyt
could
induc
antitumor
effect
may
depend
level
lymphocyt
affin
highaffin
cell
effect
tumor
cell
inhibit
lowaffin
cell
otherwis
invalid
tcell
activ
could
lead
reduct
cell
prolifer
addit
prolifer
cell
play
weak
role
kill
tumor
cell
led
tumor
toler
therefor
presum
cpg
combin
tumor
cell
lysat
effect
cell
activ
cell
may
higher
affin
